- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
- Interventions
- Semaglutide, Placebo (Semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 54
- States / cities
- Fairhope, Alabama • Mobile, Alabama • Beverly Hills, California + 47 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 2,458
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Failure
- Interventions
- Chronicle Implantable Hemodynamic Monitor, Standard of Care
- Device · Other
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 22 more
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
- Interventions
- AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy
- Device · Drug
- Lead sponsor
- Ancora Heart, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 96
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 75 more
- Conditions
- Cardiovascular Diseases, Heart Diseases, Atherosclerosis, Coronary Disease, Hypertension, Cerebrovascular Disorders
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 35 Years to 84 Years
- Enrollment
- 5,306 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2025
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Heart Failure, Mild Cognitive Impairment
- Interventions
- Vita, Com, Vita+Com
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Heart Failure
- Interventions
- Decision Making Intervention
- Other
- Lead sponsor
- Saint Luke's Health System
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Heart Failure, Congestive
- Interventions
- on-demand audio messages of heart failure education themes
- Other
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,487 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 4
- States / cities
- Cleveland, Ohio • Mayfield Heights, Ohio • Medina, Ohio
- Conditions
- Heart Failure, Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association Class IV
- Interventions
- POWERbreathe KH2, Usual Care
- Device · Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Heart Failure
- Interventions
- Vivio measurement
- Diagnostic Test
- Lead sponsor
- Ventric Health, LLC
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Long Beach, California • Los Angeles, California • San Diego, California + 1 more
- Conditions
- Chronic Heart Failure
- Interventions
- HeartWare® VAS, Control LVAD
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 39 more
- Conditions
- Cardiomyopathy
- Interventions
- Three-lead CRT-D (Defibrillator)
- Device
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 6 more
- Conditions
- Congestive Heart Failure
- Interventions
- carvedilol, placebo
- Drug
- Lead sponsor
- Shaddy, Robert, M.D.
- Individual
- Eligibility
- 1 Day to 17 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more
- Conditions
- Heart Failure, Anemia, Cardiovascular Disease, Ventricular Dysfunction, Congestive Heart Failure
- Interventions
- Darbepoetin alfa, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 254
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 195 more
- Conditions
- Heart Failure, Ischemic Cardiomyopathy, ICD Patients
- Interventions
- 18F-metaFluorobenzylguanidine, Rubidium-82
- Drug
- Lead sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Congestive Heart Failure
- Interventions
- SR121463B
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Heart Failure, Cardiac Imaging Techniques, Congenital Heart Defects
- Interventions
- Not listed
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- STM01
- Drug
- Lead sponsor
- Secretome Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Dallas, Texas
- Conditions
- Heart Failure
- Interventions
- Exercise
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Columbia, South Carolina
- Conditions
- Heart Failure
- Interventions
- Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 14
- States / cities
- Dothan, Alabama • Huntsville, Alabama • Inverness, Florida + 11 more
- Conditions
- Heart Failure, Congestive
- Interventions
- GSK2798745 Micronized API without SLS and hypermellose (Tablet A), GSK2798745 Micronized API with SLS and hypermellose (Tablet B), GSK2798745 milled API without SLS and hypermellose (Tablet C)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Cardiogenic Shock, Heart Failure, Inflammation
- Interventions
- Methylprednisone, Standard of Care (SOC)
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Iron-deficiency, Heart Failure With Preserved Ejection Fraction
- Interventions
- Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric], Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Neuromuscular electrical stimulation
- Device
- Lead sponsor
- University of Vermont Medical Center
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure
- Interventions
- tezosentan
- Drug
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 735 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 5 more